UPDATE: Piper Jaffray Resumes Coverage on Celgene as 2014 Biotech Sector Outlook Remains Strong
November 27, 2013 at 11:15 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer resumed coverage on Celgene Corporation (NASDAQ: CELG ) with a Neutral rating and $170.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the